Effect of Paricalcitol Over Vessel Wall (MICROBUB)

Effice Research

Status and phase

Terminated

Phase 4

Conditions

Nephropathy

Treatments

Drug: Paricalcitol

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT02372695

MICROBUB-2011-01

2011-002554-30 (EudraCT Number)

Details and patient eligibility

About

To provide evidence based prospectives of the potential benefit effects of paricalcitol, an analog of vitamin D, over the prevention / retardation of the progression of neoangiogenesis (vessels), atherosclerosis and vascular calcification.

Full description

Providing prospective results based on evidence of potential beneficial effects of paricalcitol, an analogue of vitamin D in the prevention / delay of progression of neoangiogenesis (vessels), atherosclerosis and vascular calcification.

Enrollment

50 patients

Sex

All

Ages

50 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients aged between 50 and 75 years.
Chronic kidney disease stage 5 D or 4-5 No D as calculated glomerular filtration rate (MDRD).
Concentration of intact parathyroid hormone (iPTH): 150-400 pg/ml.
Plasma concentrations of 25 (OH) vitamin D <30 ng/ml.
Without vitamin D supplementation for 3 months before the study.
Serum P> 3.8 mg / dl.
Serum Ca> 9.8 mg / dl.
No history of cardiovascular events (angina or myocardial infarction, stroke, peripheral arterial disease).
No exclusion criteria for the use of contrast.